Modern treatment options in epithelial ovarian carcinoma

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 1, 1998, Pages 29-32

  Benjamin, Ivor ^a   Rubin, Stephen C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN;

ARTHRALGIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0031889242     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199802000-00006     Document Type: Review

References (19)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997]. CA Cancer J Clin 1997; 47:5-27.
2. Partridge EE, Phillips JL, Menck HR. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996; 78:2236-2246.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23 (Suppl 12):40-47.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6. An important, well-controlled, randomized trial showing improved survival using paclitaxel in combination with cisplatin when compared with cisplatin and Cyclophosphamide.
5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Comparison of combination therapy with paclitaxel and cisplatin versus Cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 1997; 24 (Suppl 2):S2-13-S2-16.
6. du Bois A, Luck HJ, Meier W, Mobus V, Costa S, Richter B, et al. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol 1997; 24 (Suppl 11):S11-28-S11-33. An interim analysis of a large phase III trial comparing carboplatin in combination wrth paclitaxel versus cisplatin in combination with paclitaxel. Toxicity appears to be reduced with carboplatin. Combined response data are similar to GOG 111.
7. 2 over 3 h) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin Oncol 1997; 24 (Suppl 15):S15-36-S15-39. In this study, less nausea and vomiting was noted in the carboplatin arm when compared with the cisplatin-containing regimen.
8. Meerpohl HG, du Bois A, Luck HJ, Kuhnle H, Mobus V, Kreienberg R, et al. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial. Semin Oncol 1997; 24 (Suppl 2):S2-17-S2-22. Phase I data suggesting reduced neurotoxicity when carboplatin is combined with paclitaxel when compared with cisplatin combinations.
9. ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol 1997; 24 (Suppl 5):S5-19-S5-25.
10. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]. J Clin Oncol 1997; 15:2183-2193. In this study an overall response rate of 20% was observed for treatment with topotecan.
11. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66:480-486.
12. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire III WP, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15:177-186.
13. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study [see comments]. J Clin Oncol 1996; 14:3056-3061.
14. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63:89-93. This study reported a 13% response rate noted in heavily pre-treated patients.
15. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993. In this study an impressive 25.7% response rate was seen in heavily pre-treated patients, with acceptable levels of toxicity.
16. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, et al. Paclitaxel delivered as a 3 h infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996; 62:166-168. The important observation of a high rate and degree of peripheral neurotoxicity when cisplatin was combined with paclitaxel as a 3 h infusion is reported in this study.
17. du Bois A, Luck HJ, Bauknecht T, Mobus V, Bochtler H, Diergarten K, et al. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 1997; 8:355-361.
18. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748-1756.
19. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-1955. A well-controlled randomized trial showing a survival benefit for a first-line intraperitoneal regimen. Unfortunately, study accrual pre-dated the introduction of paclitaxel.